TY - JOUR
T1 - Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents
T2 - A propensity score matching study
AU - Kim, Yong Hoon
AU - Her, Ae Young
AU - Rha, Seung Woon
AU - Choi, Byoung Geol
AU - Choi, Se Yeon
AU - Byun, Jae Kyeong
AU - Park, Yoonjee
AU - Kang, Dong Oh
AU - Jang, Won Young
AU - Kim, Woohyeun
AU - Choi, Woong Gil
AU - Kang, Tae Soo
AU - Ahn, Jihun
AU - Park, Sang Ho
AU - Park, Ji Young
AU - Lee, Min Ho
AU - Choi, Cheol Ung
AU - Park, Chang Gyu
AU - Seo, Hong Seog
AU - Roever, Leonardo
PY - 2019/8/1
Y1 - 2019/8/1
N2 - There are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZES) with phosphorylcholine polymer (P)-ZES. The aim of this study was to compare the efficacy and safety of B-ZES with P-ZES in patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period.One thousand two hundred fifty four patients who underwent PCI with P-ZES (Endeavor [ZES-E] or Endeavor sprint [ZES-S], n=356) or B-ZES (Endeavor resolute [ZES-R] or Resolute Integrity [ZES-I], n=889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR), and the secondary endpoint was stent thrombosis (ST).After PSM, 2 propensity-matched (PSM) groups (275 pairs, n=550, C-statistic=0.730) were generated. During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920-2.526; P=.101) and ST (HR, 1.248; 95% CI, 0.335-4.4649; P=.741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank P=.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank P=.025).In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI.
AB - There are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZES) with phosphorylcholine polymer (P)-ZES. The aim of this study was to compare the efficacy and safety of B-ZES with P-ZES in patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period.One thousand two hundred fifty four patients who underwent PCI with P-ZES (Endeavor [ZES-E] or Endeavor sprint [ZES-S], n=356) or B-ZES (Endeavor resolute [ZES-R] or Resolute Integrity [ZES-I], n=889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR), and the secondary endpoint was stent thrombosis (ST).After PSM, 2 propensity-matched (PSM) groups (275 pairs, n=550, C-statistic=0.730) were generated. During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920-2.526; P=.101) and ST (HR, 1.248; 95% CI, 0.335-4.4649; P=.741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank P=.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank P=.025).In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI.
KW - BioLinx
KW - Polymer
KW - Zotarolimus
KW - clinical outcomes
KW - drug-eluting stent
KW - phoshorylcholine
UR - http://www.scopus.com/inward/record.url?scp=85070559631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070559631&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000016767
DO - 10.1097/MD.0000000000016767
M3 - Article
C2 - 31393396
AN - SCOPUS:85070559631
VL - 98
JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
SN - 0025-7974
IS - 32
M1 - e16767
ER -